

Guntram Deichsel, Biberach an der Riss

Senn's Game Theoretic Approach to Project Prioritization in the Pharmaceutical Industry

Gambling: Toss three coins - 2 games

A B C D

A: 3 at once - B: one after the other, stop option

Win if three tails turn up	Game A: pay total stake first	Game B: pay stake stepwise
Stake	3	$1+1+1 = 3$
A priori probability of success	$(1/2)^3 = 1/8$	$(1/2)^3 = 1/8$
Reward	25	20
Net reward if successful	22	17

Which game is the more attractive one?

Game tree - 3 coins, accounts over time

A B C D

Calculating
expected final account

A	B
$22/8$	$17/8$
$-21/8$	$-1/2$
	$-2/4$
	$-3/8$

$1/8$

$6/8$

Decision analysis

Expected reward:

game A: $25/8$

game B: $20/8$

Expected costs:

game A: $3 = 24/8$

game B: $1/2 + 2/4 + 3/4 = 14/8$

Expected net reward:

game A: $25/8 - 24/8 = 1/8$

game B: $20/8 - 14/8 = 6/8$ - sixfold!!

Pearson Index: cost & probability architecture

A B C D

Expected reward:

game A: $25/8$

game B: $20/8$

Expected cost:

game A: 3

game B: $1/2 + 2/4 + 3/4 = 14/8$

Pearson Index:

$(E(\text{reward}) - E(\text{cost})) / E(\text{cost})$

Game A: $(25/8 - 3) / 3$, Game B: $(20 - 14) / 14$

$= 0.042$ $= 0.429$


Four hypothetical development projects

A B C D

	----- Project -----			
Stage	A	B	C	D
1: cost P(success)	3 0.8	3 0.4	1 0.8	1 0.4
2: cost P(success)	2 0.6	2 0.6	2 0.6	2 0.6
3: cost P(success)	1 0.4	1 0.8	3 0.4	3 0.8
Total cost	6	6	6	6
<i>overall P(success)</i>	0.192	0.192	0.192	0.192
Reward if successful	28	28	28	28
<i>Expected costs</i>	5.08	4.04	4.04	2.52
<i>Expected reward</i>	5.376	5.376	5.376	5.376
Expected net reward	0.296	1.336	1.336	2.856
Pearson Index	0.058	0.331	0.331	1.133

True 3-stage project - costs & reward to be time discounted!


A B C D



A model for a 1-stage and a 2-stage project

A B C D

t year per stage, equal P(success) & cost per stage,
 $\mathbf{a} = \exp(-a t)$ - cost, $\mathbf{b} = \exp(-b t)$ reward discount factor




$$E(r) = pr \mathbf{b}$$

$$E(c) = c$$

Pearson Index $D_n = E(r)/E(c) - 1$

With (realistic) $t=2$, $p=0.1$
 $c=1$, $r=15$, $a=0.06$, $b=0.09$

$$D_1 = 0.253$$



$$E(c) = c/2$$

$$+ p^{1/2} \mathbf{a} c/2$$

$$E(r) = pr \mathbf{b}^2$$

$$D_2 = 0.634$$

Time "penalties" in an n-stage project - reflected in the Pearson Index

A B C D


$$D_n = pr \mathbf{b}^n / [(c/n) (1 - \mathbf{a}^n p) / (1 - \mathbf{a} p^{1/n})] - 1$$

(cost term gained via geometric series summation formula)

Expected

Stages	reward	cost	D (P.I.)
1	1.25	1.00	0.2529
2	1.05	0.64	0.6346
3	0.87	0.53	0.6585
4	0.73	0.47	0.5605
5	0.61	0.43	0.4209
6	0.51	0.40	0.2714
7	0.43	0.38	0.1259
8	0.36	0.36	-0.0099
9	0.30	0.34	-0.1336
10	0.25	0.33	-0.2446

Faster is not always better



senn.org

Regulatory hurdles can be in sponsor's interest

Statisticians: "What - more work?"

A B C D

Cf. **Put Option** - sell stocks @ purchase price in case of falling value.

Pearson Index: captures a priori the value of such an option.

This value is to be made available to
R & D portfolio managers for planning considerations.

Conclusion:

Statisticians can add value to strategic R & D planning
by "speaking the language of managers".

Suggested readings

Senn S (1996): Some Statistical Issues in Project Prioritization in the Pharmaceutical Industry.
Statistics in Medicine **15**: 2689-2702
(source of this presentation)

Bergman S, Gittins J (1985): Statistical Method for Pharmaceutical Research Planning.
New York (Dekker)

Enas GG, Andersen JS (2001): Enhancing the value delivered by the statistician throughout drug discovery and development: putting statistical science into regulated pharmaceutical innovation. Statistics in Medicine **20**: 2697-2708